



STARPHARMA SUBSIDIARY MAJOR BENEFICIARY OF US\$3.5 MILLION US DEFENSE ALLOCATION

Melbourne (Australia) 28 October 2002: Starpharma Pooled Development Limited (ASX:SPL) today announced that Dendritic Nanotechnologies Limited (DNT) is a major beneficiary of a US\$3.5 million (A\$6.3 million) grant for applied dendrimer nanotechnology research and development. The US Congress allocated the money in the defense appropriations act signed by President Bush last week. US Congressman Dave Camp announced that the grant would help create an active applied research environment at DNT for discovery and delivery of drugs and protection against biological warfare.

Starpharma CEO, Dr John Raff said: "The funding demonstrates strong US government interest in the broad range of applications of dendrimer nanotechnology, particularly its use as protection against biological and chemical warfare."

Starpharma is the major shareholder of DNT, the dendrimer nanotechnology company it established in partnership with Dr Donald A. Tomalia, a pioneer of dendrimer nanotechnology. DNT has research and development facilities at Central Michigan University (CMU) in Mt Pleasant, Michigan USA.

The US\$3.5 million grant is earmarked for the establishment of a state of the art dendrimer research facility in the CMU Technology Park. This funding will provide DNT with the facilities and equipment for the development and manufacture of specialist dendrimer products. The funding is for one year, and there are significant prospects for further funding in subsequent years. Starpharma is working with DNT on a range of projects relevant to the strategic interests of the Department of Defense.

"The grant is an indication of DNT's credibility in the field of dendrimer-based nanotechnology. DNT and Starpharma are world leaders in this area, and this level of support from the US Congress indicates the international significance of our area of expertise." Dr Raff said.

Starpharma, as well as being a major shareholder in DNT, has exclusive commercialisation rights to all pharmaceutical applications of DNT's extensive dendrimer nanotechnology IP portfolio. This grant will assist Starpharma and DNT in achieving their common business strategies directed towards the incorporation of dendrimers into new and existing proprietary commercial products, including pharmaceuticals.

CONTACTS:

Dr John Raff
Chief Executive Officer
+61 3 8532 2701
www.starpharma.com

Mr Ben Rogers
Company Secretary
+61 3 8532 2702

Congressman Dave Camp's press release can be viewed at:
<http://wwwb.house.gov/camp/newsarticle.asp>